2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Page 2 of 19 4.2 Dose and method of administration PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) EMEND (aprepitant) is available as capsules for oral administration.
Download 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION ... - ALOXI
www.aloxi.comPostoperative Nausea and Vomiting (2.1) • Adult Dosage: a single 0.075 mg intravenous dose administered over 10 seconds immediately before the induction of anesthesia.
DRUG NAME: Cisplatin
www.bccancer.bc.canausea and vomiting can occur 24 hours or longer following chemotherapy when complete emetic control had been attained on the day of cisplatin therapy.
Symptom Management Guidelines: CANCER RELATED …
www.bccancer.bc.caSymptom Management Guidelines: CANCER RELATED NAUSEA AND VOMITING. Definition Nausea: A subjective phenomenon of an unpleasant, wavelike sensation experienced in the back of the throat and/or the epigastrium. Nausea may or may not result in vomiting- it is the patient’s perception that vomiting may occur.
EMPIRIC GUIDELINES FOR TREATMENT OF CYCLIC VOMITING …
www.cvsa.org.ukMAY, 2005 EMPIRIC GUIDELINES FOR THE MANAGEMENT OF CYCLIC VOMITING SYNDROME There is as yet, no standard, evidence-based treatment regimen for CVS. Management must be individualized and “fine-tuned” during the course of the patient’s illness.
Pharmacy and Therapeutics (P&T) Summary –January 2012
www.methodistmd.orgPharmacy and Therapeutics (P&T) Summary –March 2012. Methodist Healthcare-Memphis Hospitals (MHMH) Katie Morneau, Pharm.D./Tifany Derheimer, Pharm.D.